1296 related articles for article (PubMed ID: 23494934)
21. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia.
Edwards NC; Pesa J; Meletiche DM; Engelhart L; Thompson AK; Sherr J; Dirani R
Curr Med Res Opin; 2008 Dec; 24(12):3341-55. PubMed ID: 18954497
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
[TBL] [Abstract][Full Text] [Related]
23. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.
Quintero J; Oyagüez I; González B; Cuervo-Arango I; García I; Casado MA
Clin Drug Investig; 2016 Jun; 36(6):479-90. PubMed ID: 27000061
[TBL] [Abstract][Full Text] [Related]
24. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
[TBL] [Abstract][Full Text] [Related]
25. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Chue PS; Heeg B; Buskens E; van Hout BA
Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
[TBL] [Abstract][Full Text] [Related]
27. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
Einarson TR; Zilbershtein R; Skoupá J; Veselá S; Garg M; Hemels ME
J Med Econ; 2013 Sep; 16(9):1089-95. PubMed ID: 23808900
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
Chue P; Chue J
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
31. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Carswell C; Wheeler A; Vanderpyl J; Robinson E
Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
[TBL] [Abstract][Full Text] [Related]
33. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
Gentile S
Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
[TBL] [Abstract][Full Text] [Related]
34. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
Keith S
Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
Obradovic M; Mrhar A; Kos M
Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
[TBL] [Abstract][Full Text] [Related]
37. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
[TBL] [Abstract][Full Text] [Related]
38. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
40. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
Fleeman N; McLeod C; Bagust A; Beale S; Boland A; Dundar Y; Jorgensen A; Payne K; Pirmohamed M; Pushpakom S; Walley T; de Warren-Penny P; Dickson R
Health Technol Assess; 2010 Jan; 14(3):1-157, iii. PubMed ID: 20031087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
